Use

AlloSure Lung is intended to assess the probability of lung allograft rejection in lung transplant recipients, particularly to inform clinical decision-making regarding the necessity of allograft biopsy in conjunction with standard-of-care clinical assessment. It measures the percent of donor‑derived cell‑free DNA (dd‑cfDNA) in peripheral blood as an indicator of graft injury; elevated dd‑cfDNA levels are associated with acute cellular rejection (ACR), antibody‑mediated rejection (ABMR) and chronic lung allograft dysfunction (CLAD). Interpretation should consider clinical context, and results are not intended for multi‑organ transplant recipients, pregnant recipients, or those with recent transfusions or biopsies within 24 hours prior to sample collection. Also, recent invasive procedures may transiently elevate dd‑cfDNA levels and affect interpretation.